White Paper
Opportunities in Evidence Generation for Tumor-agnostic Targeted Therapies to Better Support Health Technology Assessments in Europe
Sep 15, 2022
Download

Tumor-agnostic therapies are among the most challenging for regulators and health technology assessment (HTA) bodies to assess. This whitepaper explores how wider use of Real World Evidence can support faster and more sustainable access to patients.

Contact Us